Literature DB >> 16982694

The middle domain of Hsp90 acts as a discriminator between different types of client proteins.

Patricija Hawle1, Martin Siepmann, Anja Harst, Marco Siderius, H Peter Reusch, Wolfgang M J Obermann.   

Abstract

The mechanism of client protein activation by Hsp90 is enigmatic, and it is uncertain whether Hsp90 employs a common route for all proteins. Using a mutational analysis approach, we investigated the activation of two types of client proteins, glucocorticoid receptor (GR) and the kinase v-Src by the middle domain of Hsp90 (Hsp90M) in vivo. Remarkably, the overall cellular activity of v-Src was highly elevated in a W300A mutant yeast strain due to a 10-fold increase in cellular protein levels of the kinase. In contrast, the cellular activity of GR remained almost unaffected by the W300A mutation but was dramatically sensitive to S485Y and T525I exchanges. In addition, we show that mutations S485Y and T525I in Hsp90M reduce the ATP hydrolysis rate, suggesting that Hsp90 ATPase is more tightly regulated than assumed previously. Therefore, the activation of GR and v-Src has various demands on Hsp90 biochemistry and is dependent on separate functional regions of Hsp90M. Thus, Hsp90M seems to discriminate between different substrate types and to adjust the molecular chaperone for proper substrate activation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982694      PMCID: PMC1636778          DOI: 10.1128/MCB.02188-05

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  36 in total

1.  Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release.

Authors:  Jason Fontana; David Fulton; Yan Chen; Todd A Fairchild; Timothy J McCabe; Naoya Fujita; Takashi Tsuruo; William C Sessa
Journal:  Circ Res       Date:  2002-05-03       Impact factor: 17.367

2.  The Hsp90-binding peptidylprolyl isomerase FKBP52 potentiates glucocorticoid signaling in vivo.

Authors:  Daniel L Riggs; Patricia J Roberts; Samantha C Chirillo; Joyce Cheung-Flynn; Viravan Prapapanich; Thomas Ratajczak; Richard Gaber; Didier Picard; David F Smith
Journal:  EMBO J       Date:  2003-03-03       Impact factor: 11.598

Review 3.  Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery.

Authors:  William B Pratt; David O Toft
Journal:  Exp Biol Med (Maywood)       Date:  2003-02

4.  Stimulation of the weak ATPase activity of human hsp90 by a client protein.

Authors:  Stephen H McLaughlin; Harvey W Smith; Sophie E Jackson
Journal:  J Mol Biol       Date:  2002-01-25       Impact factor: 5.469

5.  Localization of sites of interaction between p23 and Hsp90 in solution.

Authors:  Maria A Martinez-Yamout; Rani P Venkitakrishnan; Nicholas E Preece; Gerard Kroon; Peter E Wright; H Jane Dyson
Journal:  J Biol Chem       Date:  2006-03-25       Impact factor: 5.157

6.  Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions.

Authors:  Philippe Meyer; Chrisostomos Prodromou; Bin Hu; Cara Vaughan; S Mark Roe; Barry Panaretou; Peter W Piper; Laurence H Pearl
Journal:  Mol Cell       Date:  2003-03       Impact factor: 17.970

7.  The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains.

Authors:  C Prodromou; B Panaretou; S Chohan; G Siligardi; R O'Brien; J E Ladbury; S M Roe; P W Piper; L H Pearl
Journal:  EMBO J       Date:  2000-08-15       Impact factor: 11.598

8.  Interaction between the N-terminal and middle regions is essential for the in vivo function of HSP90 molecular chaperone.

Authors:  Shigeki Matsumoto; Etsuko Tanaka; Takayuki K Nemoto; Toshio Ono; Takashi Takagi; Jun Imai; Yoko Kimura; Ichiro Yahara; Takeshi Kobayakawa; Takao Ayuse; Kumiko Oi; Akio Mizuno
Journal:  J Biol Chem       Date:  2002-07-16       Impact factor: 5.157

9.  Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1.

Authors:  Barry Panaretou; Giuliano Siligardi; Philippe Meyer; Alison Maloney; Janis K Sullivan; Shradha Singh; Stefan H Millson; Paul A Clarke; Soren Naaby-Hansen; Rob Stein; Rainer Cramer; Mehdi Mollapour; Paul Workman; Peter W Piper; Laurence H Pearl; Chrisostomos Prodromou
Journal:  Mol Cell       Date:  2002-12       Impact factor: 17.970

Review 10.  Hsp90: a specialized but essential protein-folding tool.

Authors:  J C Young; I Moarefi; F U Hartl
Journal:  J Cell Biol       Date:  2001-07-23       Impact factor: 10.539

View more
  52 in total

1.  The conserved arginine 380 of Hsp90 is not a catalytic residue, but stabilizes the closed conformation required for ATP hydrolysis.

Authors:  Christian N Cunningham; Daniel R Southworth; Kristin A Krukenberg; David A Agard
Journal:  Protein Sci       Date:  2012-08       Impact factor: 6.725

2.  Split Renilla luciferase protein fragment-assisted complementation (SRL-PFAC) to characterize Hsp90-Cdc37 complex and identify critical residues in protein/protein interactions.

Authors:  Yiqun Jiang; Denzil Bernard; Yanke Yu; Yehua Xie; Tao Zhang; Yanyan Li; Joseph P Burnett; Xueqi Fu; Shaomeng Wang; Duxin Sun
Journal:  J Biol Chem       Date:  2010-04-22       Impact factor: 5.157

3.  Hsp90 cochaperone Aha1 is a negative regulator of the Saccharomyces MAL activator and acts early in the chaperone activation pathway.

Authors:  Fulai Ran; Nidhi Gadura; Corinne A Michels
Journal:  J Biol Chem       Date:  2010-02-22       Impact factor: 5.157

4.  Nucleotide-dependent interaction of Saccharomyces cerevisiae Hsp90 with the cochaperone proteins Sti1, Cpr6, and Sba1.

Authors:  Jill L Johnson; Agnieszka Halas; Gary Flom
Journal:  Mol Cell Biol       Date:  2006-11-13       Impact factor: 4.272

Review 5.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential.

Authors:  Yanyan Li; Tao Zhang; Steven J Schwartz; Duxin Sun
Journal:  Drug Resist Updat       Date:  2009 Feb-Apr       Impact factor: 18.500

6.  Hsp90/Hsp70 chaperone machine regulation of the Saccharomyces MAL-activator as determined in vivo using noninducible and constitutive mutant alleles.

Authors:  Fulai Ran; Mehtap Bali; Corinne A Michels
Journal:  Genetics       Date:  2008-05-05       Impact factor: 4.562

Review 7.  Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.

Authors:  Alison Donnelly; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

8.  Selective activation of protein kinase C∊ in mitochondria is neuroprotective in vitro and reduces focal ischemic brain injury in mice.

Authors:  Xiaoyun Sun; Grant R Budas; Lijun Xu; George E Barreto; Daria Mochly-Rosen; Rona G Giffard
Journal:  J Neurosci Res       Date:  2013-02-21       Impact factor: 4.164

9.  The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin.

Authors:  Veronika Kvardova; Roman Hrstka; Dawid Walerych; Petr Muller; Eva Matoulkova; Veronika Hruskova; Dagmar Stelclova; Petr Sova; Borivoj Vojtesek
Journal:  Mol Cancer       Date:  2010-06-15       Impact factor: 27.401

10.  Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimer.

Authors:  Giulia Morra; Gennady Verkhivker; Giorgio Colombo
Journal:  PLoS Comput Biol       Date:  2009-03-20       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.